Fragmented processes are stalling progress. By aligning CDMOs through transparency and standards, developers can move past the COGS obsession and stabilize the supply chain.
- Reimagining HACCP And Other Process Flow Risk Analysis Methods Using Relational Risk Analysis
- November 2025 — CDMO Opportunities And Threats Report
- 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026
- What 2025 FDA Warning Letters Tell Us About GMP Compliance
- Unpacking The EU's Mutual Recognition Agreements For Pharma
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
- Cell 2025, Advanced Therapies USA Taught Me Why Platformization Is No Longer Optional
- Overcoming Cell Therapy Design Challenges To Treat AML And Other Life-Threatening Diseases
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Rapid Production Of Assay Ready Cells For GPCR Drug Discovery
Accelerate drug discovery by leveraging transiently transfected assay-ready cells. This method improves assay sensitivity and reduces variability for GPCRs.
-
Studying The Spatial Architecture Of Glioblastoma
Explore how intra-tumor heterogeneity (ITH) impacts cancer progression and therapy resistance with advanced imaging platforms and custom antibody panels to reveal the spatial architecture of glioblastoma (GBM).
-
CAR-T And Laminar Flow Glovebox Isolators
A request was made for a containment system that would protect operators during lentivirus transfer, as well as provide a controlled environment for IL-2 charging of media, bead addition, and blood bag spiking.
-
A Cost-Effective Alternative To Traditional Protein A Resin Chromatography
Examine this cost-effective, efficient alternative to traditional Protein A resin chromatography for mAb production to enhance productivity and reduce costs.
-
The Business Case For EHR eSource In Clinical Trials
Examine how manual data collection challenges prompted the adoption of an eSource solution that streamlined data entry, saving time and costs, reducing errors, and accelerating a multicenter phase 2 trial.
-
N-1 Perfusion High Inoculum Fed-Batch For Reduced COGS And Easy Retrofit
Discover a company that tripled productivity and cut costs by optimizing its seed train process to achieve major gains without infrastructure expansion.
-
Biosensors For Rapid And Direct Quantitation Of AAV Capsids
Examine the performance of a biosensor for AAV capsid titer measurement that offers high-precision, broad AAV serotype binding specificity, and more.
-
The Value Of Human Panel Testing Downstream Of Donor Screening In The Allogeneic Therapy Pipeline
Allogeneic cell-based therapies require rigorous donor screening for adventitious viruses. qPCR-based assays enhance detection accuracy, sensitivity, and specificity, supplementing serological testing to ensure safer drug development and production.
-
Gene Therapy In Neurology: The Case For Optimism
Advancements in genetic therapy are revolutionizing the treatment of neurological diseases, with promising results from preclinical studies leading to clinical trials focused on safety and efficacy.
-
Anaerobic Cultivation Processes Of Probiotic Bacteria
Cultivate oxygen-sensitive probiotics with precision using real-time monitoring, microfluidic feeding, and pH control for reproducible growth and optimized microbiome and fermentation research.
NEWSLETTER ARCHIVE
- 12.19.25 -- Viability On The Line: Defining Minimum Quality For CGT Raw Materials
- 12.18.25 -- Top 10 Of 2025
- 12.18.25 -- Exploring Outsourcing's Role In CGT Scalability And Affordability
- 12.17.25 -- Transforming Cell Culture And Cell Therapy With Next-Generation Biomanufacturing
- 12.17.25 -- Advanced Therapies USA Taught Me Why Platformization Is No Longer Optional
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
- Cell 2025, Advanced Therapies USA Taught Me Why Platformization Is No Longer Optional
- Why Early Manufacturing Decisions in Cell & Gene Therapy Matter
- How Early Manufacturing Decisions Shape Long-Term Success
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections